An alternative approach for assessing drug induced seizures, using non-protected larval zebrafish

As many as 9% of epileptic seizures occur as a result of drug toxicity. Identifying compounds with seizurogenic side effects is imperative for assessing compound safety during drug development, however, multiple marketed drugs still have clinical associations with seizures. Moreover, current approaches for assessing seizurogenicity, namely rodent EEG and behavioural studies, are highly resource intensive. This being the case, alternative approaches have been postulated for assessing compound seizurogenicity, including in vitro, in vivo, and in silico methods. In this thesis, experimental work is presented supporting the use of larval zebrafish as a candidate model organism for developing new seizure liability screening approaches. Larval zebrafish are translucent, meaning they are highly amenable to imaging approaches while offering a more ethical alternative to mammalian research. Zebrafish are furthermore highly fecund facilitating capacity for both high replication and high throughput. The primary goal of this thesis was to identify biomarkers in larval zebrafish, both behavioural and physiological, of compounds that increase seizure liability. The efficacy of this model organism for seizure liability testing was assessed through exposure of larval zebrafish to a mechanistically diverse array of compounds, selected for their varying degrees of seizurogenicity. Their central nervous systems were monitored using a variety of different techniques including light sheet microscopy, local field potential recordings, and behavioural monitoring. Data acquired from these measurements were then analysed using a variety of techniques including frequency domain analysis, clustering, functional connectivity, regression, and graph theory. Much of this analysis was exploratory in nature and is reflective of the infancy of the field. Experimental findings suggest that larval zebrafish are indeed sensitive to a wide range of pharmacological mechanisms of action and that drug actions are reflected by behavioural and direct measurements of brain activity. For example, local field potential recordings revealed electrographic responses akin to pre-ictal, inter-ictal and ictal events identified in humans. Ca2+ imaging using light sheet microscopy found global increases in fluorescent intensity and functional connectivity due to seizurogenic drug administration. In addition, [2] further functional connectivity and graph analysis revealed macroscale network changes correlated with drug seizurogenicity and mechanism of action. Finally, analysis of swimming behaviour revealed a strong correlation between high speed swimming behaviours and administration of convulsant compounds. In conclusion, presented herein are data demonstrating the power of functional brain imaging, LFP recordings, and behavioral monitoring in larval zebrafish for assessing the action of neuroactive drugs in a highly relevant vertebrate model. These data help us to understand the relevance of the 4 dpf larval zebrafish for neuropharmacological studies and reveal that even at this early developmental stage, these animals are highly responsive to a wide range of neuroactive compounds across multiple primary mechanisms of action. This represents compelling evidence of the potential utility of larval zebrafish as a model organism for seizure liability testing

Concordant spatio-temporal patterns of brain activation in zebrafish exposed to compounds with similar pharmacodynamics or with similar seizurogenic potential.

Abstract Drug development is a highly resource intensive process that uses large numbers of animals for assessing the safety and efficacy of drugs prior to clinical testing. Improving the efficiency of drug development in terms of financial expenditure and number of animals used is therefore of utmost concern, not only to industry, but also to animal welfare organisations such as the NC3Rs. Poor efficiency in drug development largely stems from drug attrition, particularly attrition in the latter stages of the testing due to the large amount of resources expended at the point of failure. It is therefore imperative that deleterious off-target effects are identified as early as possible. However, typically, identification of seizure as a side-effect of drugs is performed in the later stages of development due to the highly intensive and low-throughput nature of seizure assays. At which point, if a compound fails, a large amount of resources have been squandered. There therefore exists a need for high-throughput and relatively inexpensive seizure liability assays that can be used early in drug development to prevent compounds destined for failure undergoing unnecessary resource intensive testing. In this thesis we propose a refined approach using non-invasive imaging techniques in non-protected life stage zebrafish as a method for the detection of seizurogenic compounds early in drug development. In addition, we highlight its utility for elucidating the pharmacodynamics of compounds. In this study, a transgenic zebrafish line containing a GCaMP6s calcium sensor under the control of the pan-neuronal promoter elavl3 was used for functional profiling of compounds with varied pharmacologies. Light sheet microscopy was used to record fluorescent activity in three spatial dimensions over time (4-dimensions) from the zebrafish brain after exposure to forty-three different compounds with varied pharmacodynamics and seizure liability profiles. Hierarchical clustering was employed in order to assess if compounds with seizurogenic activity or similar pharmacodynamics elicited specific functional brain activity. It was found that compounds with dopaminergic and serotonergic mechanisms of action elicited highly specific and similar brain activity patterns and that non-seizurogenic drugs also clustered separately from seizurogenic ones. Subsequent analyses, focussed on the utilisation of machine learning techniques, developing a model that could be used to discriminate between compounds with and without potentially seizurogenic effects. It is clear, from the analyses presented here, that drugs do in fact elicit specific brain patterns in zebrafish and that these brain patterns are effectively detected using light sheet microscopy. This system is highly applicable for use within the drug industry and even in its relatively preliminary stages provided an accurate method of discriminating between compounds based on their physiological effects in zebrafish

4-dimensional functional profiling in the convulsant-treated larval zebrafish brain

This is the final version of the article. Available from Springer Nature via the DOI in this record.Functional neuroimaging, using genetically-encoded Ca(2+) sensors in larval zebrafish, offers a powerful combination of high spatiotemporal resolution and higher vertebrate relevance for quantitative neuropharmacological profiling. Here we use zebrafish larvae with pan-neuronal expression of GCaMP6s, combined with light sheet microscopy and a novel image processing pipeline, for the 4D profiling of chemoconvulsant action in multiple brain regions. In untreated larvae, regions associated with autonomic functionality, sensory processing and stress-responsiveness, consistently exhibited elevated spontaneous activity. The application of drugs targeting different convulsant mechanisms (4-Aminopyridine, Pentylenetetrazole, Pilocarpine and Strychnine) resulted in distinct spatiotemporal patterns of activity. These activity patterns showed some interesting parallels with what is known of the distribution of their respective molecular targets, but crucially also revealed system-wide neural circuit responses to stimulation or suppression. Drug concentration-response curves of neural activity were identified in a number of anatomically-defined zebrafish brain regions, and in vivo larval electrophysiology, also conducted in 4dpf larvae, provided additional measures of neural activity. Our quantification of network-wide chemoconvulsant drug activity in the whole zebrafish brain illustrates the power of this approach for neuropharmacological profiling in applications ranging from accelerating studies of drug safety and efficacy, to identifying pharmacologically-altered networks in zebrafish models of human neurological disorders.This work was funded by the Biological and Biotechnology Research Council (CASE studentship BB/L502510/1, with AstraZeneca Safety Health and Environment), and by the University of Exeter and AstraZeneca

Differential electrographic signatures generated by mechanistically-diverse seizurogenic compounds in the larval zebrafish brain.

This is the final version. Available from the Society for Neuroscience via the DOI in this record. We assessed similarities and differences in the electrographic signatures of local field potentials (LFPs) evoked by different pharmacological agents in zebrafish larvae. We then compared and contrasted these characteristics with what is known from electrophysiological studies of seizures and epilepsy in mammals, including humans. Ultimately, our aim was to phenotype neurophysiological features of drug-induced seizures in larval zebrafish for expanding knowledge on the translational potential of this valuable alternative to mammalian models. LFPs were recorded from the midbrain of 4-d-old zebrafish larvae exposed to a pharmacologically diverse panel of seizurogenic compounds, and the outputs of these recordings were assessed using frequency domain analysis. This included analysis of changes occurring within various spectral frequency bands of relevance to mammalian CNS circuit pathophysiology. From these analyses, there were clear differences in the frequency spectra of drug-exposed LFPs, relative to controls, many of which shared notable similarities with the signatures exhibited by mammalian CNS circuits. These similarities included the presence of specific frequency components comparable to those observed in mammalian studies of seizures and epilepsy. Collectively, the data presented provide important information to support the value of larval zebrafish as an alternative model for the study of seizures and epilepsy. These data also provide further insight into the electrophysiological characteristics of seizures generated in nonmammalian species by the action of neuroactive drugs.National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs

Functional brain imaging in larval zebrafish for characterising the effects of seizurogenic compounds acting via a range of pharmacological mechanisms

This is the final version. Available on open access from Wiley via the DOI in this recordData availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions.Background and Purpose Functional brain imaging using genetically encoded Ca2+ sensors in larval zebrafish is being developed for studying seizures and epilepsy as a more ethical alternative to rodent models. Despite this, few data have been generated on pharmacological mechanisms of action other than GABAA antagonism. Assessing larval responsiveness across multiple mechanisms is vital to test the translational power of this approach, as well as assessing its validity for detecting unwanted drug‐induced seizures and testing antiepileptic drug efficacy. Experimental Approach Using light‐sheet imaging, we systematically analysed the responsiveness of 4 days post fertilisation (dpf; which are not considered protected under European animal experiment legislation) transgenic larval zebrafish to treatment with 57 compounds spanning more than 12 drug classes with a link to seizure generation in mammals, alongside eight compounds with no such link. Key Results We show 4dpf zebrafish are responsive to a wide range of mechanisms implicated in seizure generation, with cerebellar circuitry activated regardless of the initiating pharmacology. Analysis of functional connectivity revealed compounds targeting cholinergic and monoaminergic reuptake, in particular, showed phenotypic consistency broadly mapping onto what is known about neurotransmitter‐specific circuitry in the larval zebrafish brain. Many seizure‐associated compounds also exhibited altered whole brain functional connectivity compared with controls. Conclusions and Implications This work represents a significant step forward in understanding the translational power of 4dpf larval zebrafish for use in neuropharmacological studies and for studying the events driving transition from small‐scale pharmacological activation of local circuits, to the large network‐wide abnormal synchronous activity associated with seizures.Biotechnology and Biological Sciences Research Council (BBSRC)National Centre for the Replacement Refinement and Reduction of Animals in ResearchUniversity of ExeterMedical Research Council (MRC)AstraZenecaEuropean Unio

Gaseous phase coal surface modification

In this report, we present an improved, feasible and potentially cost effective method of cleaning and beneficiating ultrafine coal. Increased mechanization of mining methods and the need towards depyritization, and demineralization have led to an increase in the quantity of coal fines generated in recent times. For example, the amount of {minus}100 mesh coal occurring in coal preparation plant feeds now typically varies from 5 to 25% of the total feed. Environmental constraints coupled with the greatly increased cost of coal have made it increasingly important to recover more of these fines. Our method chemically modifies the surface of such coals by a series of gaseous phase treatments employing Friedel-Crafts reactions. By using olefins (ethene, propene and butene) and hydrogen chloride catalyst at elevated temperature, the surface hydrophobicity of coal is enhanced. This increased hydrophobicity is manifest in surface phenomena which reflect conditions at the solid/liquid interphase (zeta potential) and those which reflect conditions at the solid/liquid/gas interphases (contact angle, wettability and floatability)